Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?
The fact that lipoprotein(a) levels should be regarded as a causal residual risk factor in the atherosclerotic cardiovascular diseases (ASCVD) is now a no-brainer. This review article aims to summarize the latest evidence supporting the causal role of lipoprotein(a) in ASCVD and the potential strate...
| المؤلفون الرئيسيون: | , , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
Elsevier
2024-12-01
|
| سلاسل: | Atherosclerosis Plus |
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://www.sciencedirect.com/science/article/pii/S2667089524000452 |